Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib

ConclusionsThis analysis suggests that palbociclib exposure has no impact on PFS when the dose reduction algorithm from palbociclib clinical trials is used. There is no difference in efficacy between Asians and non-Asians, despite the higher level of dose reductions in Asians.PfizerNCT01740427.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research